Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery

Circulation

Volumn 132, Issue 23, 2015, Pages 2248-2258

  Bellinger, Andrew M ^a   Arteaga, Carlos L ^b,c   Force, Thomas ^c   Humphreys, Benjamin D ^d   Demetri, George D ^a,e   Druker, Brian J ^f   Moslehi, Javid J ^c,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cardiotoxicity; drug evaluation; molecular targeted therapy; pre eclampsia; protein tyrosine kinases; translational medical research

Indexed keywords

BOSUTINIB; CARFILZOMIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERDAFITINIB; IMATINIB; LENALIDOMIDE; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PONATINIB; PROTEIN TYROSINE KINASE; THALIDOMIDE; TRASTUZUMAB; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ATHEROSCLEROSIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; EXPERIMENTAL PULMONARY HYPERTENSION; EXTRACELLULAR MATRIX; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERPHOSPHATEMIA; INTRACELLULAR SIGNALING; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PULMONARY HYPERTENSION; RECEPTOR DOWN REGULATION; REVIEW; THROMBOSIS; TUMOR MICROENVIRONMENT; VASOSPASM; ANIMAL; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; METABOLISM; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS;

EID: 84949471785     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.010484     Document Type: Review

References (95)

1. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Childhood Cancer Survivor Study Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006 355 1572 1582. doi: 10.1056/NEJMsa060185.
2. Hull MC, Morris CG, Pepine CJ, Mendenhall NP, Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003 290 2831 2837. doi: 10.1001/jama.290.21.2831.
3. Moslehi J, The cardiovascular perils of cancer survivorship. N Engl J Med 2013 368 1055 1056. doi: 10.1056/NEJMe1215300.
4. Krause DS, Van Etten RA, Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005 353 172 187. doi: 10.1056/NEJMra044389.
5. López-Otín C, Hunter T, The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 2010 10 278 292. doi: 10.1038/nrc2823.
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 344 1031 1037. doi: 10.1056/NEJM200104053441401.
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD, Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001 344 1052 1056. doi: 10.1056/NEJM200104053441404.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 177 182
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344 783 792. doi: 10.1056/NEJM200103153441101.
10. Cote GM, Sawyer DB, Chabner BA, ERBB2 inhibition and heart failure. N Engl J Med 2012 367 2150 2153. doi: 10.1056/NEJMcibr1203156.
11. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999 17 2639 2648
12. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM, Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 2014 32 2159 2165. doi: 10.1200/JCO.2013.53.9288.
13. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C, Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995 378 394 398. doi: 10.1038/378394a0.
14. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G, Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995 378 390 394. doi: 10.1038/378390a0.
15. De Keulenaer GW, Doggen K, Lemmens K, The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 2010 106 35 46. doi: 10.1161/CIRCRESAHA.109.205906.
16. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA, Neuregulins promote survival and growth of cardiac myocytes: persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998 273 10261 10269
17. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM, Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002 105 1551 1554
18. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF, ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002 8 459 465. doi: 10.1038/nm0502-459.
19. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB, Cappola TP, Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009 120 310 317. doi: 10.1161/CIRCULATIONAHA.109.856310.
20. Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M, Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006 48 1438 1447. doi: 10.1016/j.jacc.2006.05.057.
21. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, Amor R, Liu X, Li XY, Zhou MD, Graham RM, Macdonald PS, Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 2011 13 83 92. doi: 10.1093/eurjhf/hfq152.
22. Folkman J, Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 285 1182 1186. doi: 10.1056/NEJM197111182852108.
23. Folkman J, Merler E, Abernathy C, Williams G, Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971 133 275 288
24. Kerbel RS, Tumor angiogenesis. N Engl J Med 2008 358 2039 2049. doi: 10.1056/NEJMra0706596.
25. Shen C, Kaelin WG Jr, The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013 23 18 25. doi: 10.1016/j.semcancer.2012.06.001.
26. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 362 841 844. doi: 10.1038/362841a0.
27. Bair SM, Choueiri TK, Moslehi J, Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013 23 104 113. doi: 10.1016/j.tcm.2012.09.008.
28. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ, Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005 102 11011 11016. doi: 10.1073/pnas.0504952102.
29. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006 368 1329 1338. doi: 10.1016/S0140-6736(06)69446-4.
30. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D, Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001 19 843 850
31. Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ, Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013 113 754 764. doi: 10.1161/CIRCRESAHA.113.300218.
32. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X, Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008 9 117 123. doi: 10.1016/S1470-2045(08)70003-2.
33. Zhu X, Stergiopoulos K, Wu S, Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009 48 9 17. doi: 10.1080/02841860802314720.
34. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT, Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009 27 5601 5606. doi: 10.1200/JCO.2009.23.2777.
35. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD, A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008 100 282 284. doi: 10.1093/jnci/djm311.
36. Redman CW, Sargent IL, Latest advances in understanding preeclampsia. Science 2005 308 1592 1594. doi: 10.1126/science.1111726.
37. Maynard S, Epstein FH, Karumanchi SA, Preeclampsia and angiogenic imbalance. Annu Rev Med 2008 59 61 78. doi: 10.1146/annurev.med.59.110106.214058.
38. Powe CE, Levine RJ, Karumanchi SA, Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011 123 2856 2869. doi: 10.1161/CIRCULATIONAHA.109.853127.
39. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA, Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006 12 642 649. doi: 10.1038/nm1429.
40. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003 111 649 658. doi: 10.1172/JCI17189.
41. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA, Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004 350 672 683. doi: 10.1056/NEJMoa031884.
42. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T, Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011 124 940 950. doi: 10.1161/CIRCULATIONAHA.111.034793.
43. ClinicalTrials.gov. Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia (ADENA). [ https://clinicaltrials.gov/ct2/show/record/NCT02286284. Accessed May 10, 2015.
44. Uraizee I, Cheng S, Moslehi J, Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med 2011 365 1649 1650. doi: 10.1056/NEJMc1108849.
45. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK, Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011 29 3450 3456. doi: 10.1200/JCO.2010.34.4309.
46. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007 370 2011 2019. doi: 10.1016/S0140-6736(07)61865-0.
47. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O, Rosenberger C, Keshet E, Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A 2008 105 282 287. doi: 10.1073/pnas.0707778105.
48. Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K Jr, Pati S, Bankson JA, Pasqualini R, Arap W, Bryan NS, Taegtmeyer H, Langley RR, Yao H, Kupferman ME, Entman ML, Dickinson ME, Khakoo AY, Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 2013 5 187ra69. doi: 10.1126/scitranslmed.3005066.
49. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG Jr, Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 2010 122 1004 1016. doi: 10.1161/CIRCULATIONAHA.109.922427.
50. Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, Sutcliffe D, Gerard RD, Bruick RK, Shohet RV, Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One 2010 5 e11693. doi: 10.1371/journal.pone.0011693.
51. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z, Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012 485 333 338. doi: 10.1038/nature11040.
52. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H, A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007 128 589 600. doi: 10.1016/j.cell.2006.12.036.
53. Abraham D, Hofbauer R, Schäfer R, Blumer R, Paulus P, Miksovsky A, Traxler H, Kocher A, Aharinejad S, Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res 2000 87 644 647
54. Häggström M. Wikiversity. Medical Gallery of Mikael Häggström 2014. https://en.wikiversity.org/wiki/Wikiversity-Journal-of-Medicine/Medical-gallery-of-Mikael-Häggström-2014. Accessed November 23, 2015.
55. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS, A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 2012 18 4820 4829. doi: 10.1158/1078-0432.CCR-12-0098.
56. Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS, An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res 2014 20 5918 5926. doi: 10.1158/1078-0432.CCR-14-1143.
57. Savage DG, Antman KH, Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002 346 683 693. doi: 10.1056/NEJMra013339.
58. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 355 2408 2417. doi: 10.1056/NEJMoa062867.
59. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006 12 908 916. doi: 10.1038/nm1446.
60. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010 362 2251 2259. doi: 10.1056/NEJMoa0912614.
61. Atallah E, Durand JB, Kantarjian H, Cortes J, Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007 110 1233 1237. doi: 10.1182/blood-2007-01-070144.
62. Estabragh ZR, Knight K, Watmough SJ, Lane S, Vinjamuri S, Hart G, Clark RE, A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 2011 35 49 51. doi: 10.1016/j.leukres.2010.08.020.
63. Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, Fan D, Patel SR, Benjamin RS, Khakoo AY, Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010 116 184 192. doi: 10.1002/cncr.24683.
64. Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, Laengle U, Ledieu D, Marrer E, Nussher A, Persohn E, Pognan F, Rivière GJ, Roth DR, Trendelenburg C, Tsao J, Roman D, Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 2010 34 1180 1188. doi: 10.1016/j.leukres.2010.01.004.
65. Tiribelli M, Medeot M, Cardiotoxicity of imatinib: At the heart of the problem. Leuk Res 2011 35 36 37. doi: 10.1016/j.leukres.2010.09.021.
66. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA, Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008 105 18895 18900. doi: 10.1073/pnas.0810246105.
67. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME, Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004 24 935 942. doi: 10.1161/01.ATV.0000124105.39900.db.
68. Veneri D, Franchini M, Bonora E, Imatinib and regression of type 2 diabetes. N Engl J Med 2005 352 1049 1050. doi: 10.1056/NEJM200503103521023.
69. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G, Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-Tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013 27 1310 1315. doi: 10.1038/leu.2013.69.
70. Ghofrani HA, Seeger W, Grimminger F, Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005 353 1412 1413. doi: 10.1056/NEJMc051946.
71. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F, Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005 115 2811 2821. doi: 10.1172/JCI24838.
72. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F, Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA, Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013 127 1128 1138. doi: 10.1161/CIRCULATIONAHA.112.000765.
73. Shah AM, Campbell P, Rocha GQ, Peacock A, Barst RJ, Quinn D, Solomon SD, IMPRES Investigators Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J 2015 36 623 632. doi: 10.1093/eurheartj/ehu035.
74. Medarametla V, Festin S, Sugarragchaa C, Eng A, Naqwi A, Wiedmann T, Zisman LS, PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension. Pulm Circ 2014 4 82 102. doi: 10.1086/674881.
75. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ, Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 2009 4 99 105. doi: 10.1007/s11523-009-0110-4.
76. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M, Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012 125 2128 2137. doi: 10.1161/CIRCULATIONAHA.111.079921.
77. Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, Dörken B, Valent P, Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011 103 1347 1348. doi: 10.1093/jnci/djr292.
78. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P, Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011 86 533 539. doi: 10.1002/ajh.22037.
79. Goldman JM, Ponatinib for chronic myeloid leukemia. N Engl J Med 2012 367 2148 2149. doi: 10.1056/NEJMe1210796.
80. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013 369 1783 1796. doi: 10.1056/NEJMoa1306494.
81. Groarke JD, Cheng S, Moslehi J, Cancer-drug discovery and cardiovascular surveillance. N Engl J Med 2013 369 1779 1781. doi: 10.1056/NEJMp1313140.
82. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T, AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009 16 401 412. doi: 10.1016/j.ccr.2009.09.028.
83. Wong KK, Engelman JA, Cantley LC, Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010 20 87 90. doi: 10.1016/j.gde.2009.11.002.
84. Rodon J, Braña I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC, Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014 32 670 681. doi: 10.1007/s10637-014-0082-9.
85. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J, Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012 30 282 290. doi: 10.1200/JCO.2011.36.1360.
86. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S, Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013 98 1753 1761. doi: 10.3324/haematol.2013.089334.
87. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr, The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014 343 305 309. doi: 10.1126/science.1244917.
88. Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014 343 301 305. doi: 10.1126/science.1244851.
89. Cohen P, Tcherpakov M, Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 2010 143 686 693. doi: 10.1016/j.cell.2010.11.016.
90. Shaw AT, Hsu PP, Awad MM, Engelman JA, Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013 13 772 787. doi: 10.1038/nrc3612.
91. Dienstmann R, Bahleda R, Adamo B, Rodon J, Varga A, Gazzah A, Platero S, Smit H, Perera T, Zhong B, Stuyckens K, Elsayed Y, Takimoto C, Peddareddigari V, Tabernero J, Luo FG, Soria JC, First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors-CT325. April 5-9, 2014; San Diego, CA Abstract presented at: American Association for Cancer Research
92. Zhu Y, Hawkins WG, DeNardo DG, Regramming myeloid responses to improve cancer immunotherapy. Oncoimmunology 2015 4 e974399. doi: 10.4161/2162402X.2014.974399.
93. Kroemer G, Galluzzi L, Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology 2015 4 e1008853. doi: 10.1080/2162402X.2015.1008853.
94. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001 291 319 322. doi: 10.1126/science.291.5502.319.
95. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A, Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015 3 11. doi: 10.1186/s40425-015-0057-1.